Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

Puma Biotechnology director sells over $81k in company stock

Published 2024/08/14, 03:14
PBYI
-

Puma Biotechnology, Inc. (NASDAQ:PBYI) has reported a recent transaction involving the sale of company stock by director Michael Patrick Miller. On August 12, Miller sold 23,358 shares of common stock at a weighted average price of $3.4877, netting a total of $81,465.

The transactions were executed in multiple parts, with share prices ranging from $3.4201 to $3.5501. The reported average price represents the weighted mean of these sales. Following this sale, Miller's direct holdings in Puma Biotechnology stand at 47,000 shares. This correction comes after a previous filing error reported on June 21, 2024.

The sale was disclosed in a Form 4 filing with the Securities and Exchange Commission, dated August 13, 2024. The document was signed by Chris Culotta, acting as attorney-in-fact for Michael Patrick Miller.

Investors often monitor insider transactions as they can provide insights into the company's performance and insider perspectives on the stock's value. Puma Biotechnology, based in Los Angeles, California, specializes in the development of pharmaceutical preparations and has been a player in the life sciences sector.

For those interested in the specifics of the transaction, Miller has agreed to provide full details upon request regarding the number of shares sold at each price within the reported range.

In other recent news, Puma Biotechnology reported significant developments both in the courtroom and in its financial reports. The company emerged victorious in a patent infringement lawsuit against AstraZeneca (NASDAQ:AZN) Pharmaceuticals, concerning its cancer treatment drug, Tagrisso®. A federal court upheld the validity of the patents in question, awarding $107.5 million in damages for past infringement.

In financial news, Puma Biotechnology reported a net loss of $4.5 million for the second quarter of 2024. However, the company's total revenue reached $47.1 million, with the drug NERLYNX contributing $44.4 million. Despite a decrease in new patient starts and total prescriptions year-over-year, Puma anticipates net NERLYNX product revenue to be between $183 million and $190 million for 2024.

Lastly, Puma Biotechnology has secured regulatory approvals for NERLYNX in Brazil and Saudi Arabia, indicating a focus on expanding the drug's use in the extended adjuvant setting. These are among the recent developments for the company, highlighting its ongoing legal and financial activities.

InvestingPro Insights

Amid the insider transactions at Puma Biotechnology, Inc. (NASDAQ:PBYI), investors are keenly observing the company's financial health and market performance. According to InvestingPro data, Puma Biotechnology has a market capitalization of $177.79 million, with a P/E ratio that stands at 19.89. This valuation is supported by a strong free cash flow yield, as indicated in one of the InvestingPro Tips. Moreover, the company's revenue over the last twelve months as of Q2 2024 was reported at $219.14 million, despite a slight decrease in revenue growth of -4.77% during the same period.

Another key metric that stands out is the gross profit margin, which at 73.08%, reflects the company's ability to maintain profitability in its operations. However, the stock has experienced significant volatility, with a six-month price total return of -51.22%, underscoring the stock's recent performance challenges. Despite this, analysts predict that Puma Biotechnology will be profitable this year, which is a positive signal for potential investors.

For those looking deeper into Puma Biotechnology's financials and stock performance, the InvestingPro platform offers additional insights with more InvestingPro Tips. Currently, there are six more tips available that provide a comprehensive analysis of the company's financial health, debt levels, and stock valuation. Interested readers can find these valuable tips at https://www.investing.com/pro/PBYI, offering further guidance on whether Puma Biotechnology presents a compelling investment opportunity in the life sciences sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.